The DOI matches its Crossref record; 46 of the 49 references it cites were found in a registry or an index; 15 of the 19 sources its claims cite were checked for support.
Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
Open accessAbstract
BACKGROUND: Recent evidence suggests that immunotherapy efficacy in melanoma is modulated by gut microbiota. Few studies have examined this phenomenon in humans, and none have incorporated metatranscriptomics, important for determining expression of metagenomic functions in the microbial community. METHODS: In melanoma patients undergoing immunotherapy, gut microbiome was characterized in pre-treatment stool using 16S rRNA gene and shotgun metagenome sequencing (n = 27). Transcriptional expression of metagenomic pathways was confirmed with metatranscriptome sequencing in a subset of 17. We examined associations of taxa and metagenomic pathways with progression-free survival (PFS) using 500 × 10-fold cross-validated elastic-net penalized Cox regression. RESULTS: Higher microbial community richness was associated with longer PFS in 16S and shotgun data (p < 0.05). Clustering based on overall microbiome composition divided patients into three groups with differing PFS; the low-risk group had 99% lower risk of progression than the high-risk group at any time during follow-up (p = 0.002). Among the species selected in regression, abundance of Bacteroides ovatus, Bacteroides dorei, Bacteroides massiliensis, Ruminococcus gnavus, and Blautia producta were related to shorter PFS, and Faecalibacterium prausnitzii, Coprococcus eutactus, Prevotella stercorea, Streptococcus sanguinis, Streptococcus anginosus, and Lachnospiraceae bacterium 3 1 46FAA to longer PFS. Metagenomic functions related to PFS that had correlated metatranscriptomic expression included risk-associated pathways of L-rhamnose degradation, guanosine nucleotide biosynthesis, and B vitamin biosynthesis. CONCLUSIONS: This work adds to the growing evidence that gut microbiota are related to immunotherapy outcomes, and identifies, for the first time, transcriptionally expressed metagenomic pathways related to PFS. Further research is warranted on microbial therapeutic targets to improve immunotherapy outcomes.
Overview
CoChat Summary
TL;DR
In a pilot study of 27 melanoma patients receiving immunotherapy, pre-treatment gut microbiome richness and composition were associated with progression-free survival (PFS), and metatranscriptomics identified expressed microbial pathways related to PFS. The work adds evidence that gut microbiota are related to immunotherapy outcomes and identifies transcriptionally expressed metagenomic pathways associated with PFS.
Key findings
- Higher microbial community richness was associated with longer PFS: 16S s-OTUs HR [95% CI] = 0.97 [0.95, 1.00], p = 0.02; shotgun subspecies HR [95% CI] = 0.89 [0.79, 0.99], p = 0.03.
- Clustering by overall microbiome composition divided patients into three groups with differing PFS; the low-risk group had 99% lower risk of progression than the high-risk group at any time during follow-up (HR [95% CI] = 0.01 [0.001, 0.20], p = 0.002), while the intermediate-risk group had non-significantly lower risk (HR [95% CI] = 0.10 [0.005, 2.17], p = 0.14).
- Species related to shorter PFS included Bacteroides ovatus, Bacteroides dorei, Bacteroides massiliensis, Ruminococcus gnavus, and Blautia producta; species related to longer PFS included Faecalibacterium prausnitzii, Coprococcus eutactus, Prevotella stercorea, Streptococcus sanguinis, Streptococcus anginosus, and Lachnospiraceae bacterium 3 1 46FAA.
- Metagenomic functions with correlated metatranscriptomic expression included risk-associated pathways of l-rhamnose degradation, guanosine nucleotide biosynthesis, and B vitamin biosynthesis, and protective pathways of l-isoleucine and petroselinate biosynthesis.
Methods
- Pre-treatment stool samples from 27 patients with metastatic melanoma scheduled to receive immunotherapy at NYU Langone Health from September 2016 to November 2017, with follow-up through September 2018; samples underwent 16S rRNA gene and shotgun metagenome sequencing, and a subset of 17 underwent shotgun metatranscriptome sequencing after 10 samples failed library preparation due to poor RNA quality.
- The primary endpoint was PFS, defined as disease progression or death from any cause; associations of taxa and metagenomic pathways with PFS were assessed using 500 × 10-fold cross-validated elastic-net penalized Cox regression, adjusting for age, sex, BMI, stage, number of sites of metastases, and antibiotic use in the last 6 months.
- α-diversity and β-diversity were tested with Cox proportional hazards models, MiRKAT-S, OMiSA, and clustering with log-rank tests; functional features were filtered by prevalence, abundance, and variance, and metatranscriptomic correlations were examined with Spearman’s correlation, focusing on features selected ≥ 25% of 500 times, FDR-adjusted q < 0.20, and correlated metatranscriptomic expression p < 0.05.
Limitations
- The paper states that the study is limited by its small sample size, had insufficient sample size to analyze adjuvant and metastatic patient groups separately, and could not analyze patient groups separately by immunotherapy treatment regimen.
- The paper states that metatranscriptome sequencing data were available for only a subset of 17 patients, limiting power to assess relationships of metatranscriptomic expression and relative expression with PFS.
- Evident from the text: this is a single-center pilot study with no independent validation cohort, and the observational design cannot establish causality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
9 Valid · 1 Not valid · 5 Not checked · 89 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Treatment with immunotherapy targeting checkpoint inhibitors PD-1 or CTLA-4 significantly increases survival in patients with metastatic melanoma over other standards of care [1, 2]”
§ Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients > Background
What the sources say
- Partly supportedcites [1] Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–30. sourceExperimental — accuracy not yet measured
The Results and Conclusions report significantly better survival with the PD-1 inhibitor nivolumab than with dacarbazine, but the trial was limited to previously untreated patients with metastatic melanoma without a BRAF mutation. The Conclusions and Discussion also report survival benefits for ipilimumab in other trials. The claim omits those population and comparator limits and implies a broader benefit over standards of care than this paper establishes. (LLM, conf=0.85)
- Partly supportedcites [2] Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. sourceExperimental — accuracy not yet measured
The Abstract Conclusions and Discussion report improved overall survival with the CTLA-4 blocker ipilimumab in previously treated patients with metastatic melanoma. This study did not test PD-1 blockade, and its comparator was the gp100 vaccine, not other standards of care generally. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In human melanoma patients undergoing immunotherapy, gut microbiome composition has been significantly associated with clinical response [9–12]”
§ Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients > Background
What the sources say
- Supportedcites [9] Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, NY). 2018;359(6371):97–103. source
The paper’s opening summary reports significant differences in gut microbiome diversity and composition between melanoma patients who responded to anti-PD-1 immunotherapy and those who did not. The study findings also link distinct gut microbial communities to treatment outcome. Page numbers are not provided in our copy. (LLM, conf=0.94)
- Supportedcites [10] Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science (New York, NY). 2018;359(6371):104–8. source
The paper reports analyzing pretreatment stool samples from patients with metastatic melanoma receiving immunotherapy. It states that commensal microbial composition was significantly associated with clinical response (Abstract; no page provided). (LLM, conf=0.94)
- Supportedcites [11] Frankel AE, Coughlin LA, Kim J, Froehlich TW, Xie Y, Frenkel EP, et al. Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients. Neoplasia (New York, NY). 2017;19(10):848–55. source
The Results report significant differences in the abundance of specific gut bacterial species between responders and other patients with metastatic melanoma receiving immune checkpoint therapy (P = .032–.046). This supports the claimed association between gut microbiome composition and clinical response; the Results separately note that overall microbiome diversity was not significantly different. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [12] Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368–79. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Human gut microbiota may modulate the effectiveness of immunotherapy, and anticancer immunosurveillance in general, by shaping both effector and suppressor immune cell populations through pathogen-associated molecular patterns (PAMPs), antigens, and metabolites [40].”
§ Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients > Discussion
What the sources say
- Supportedcites [40] Zitvogel L, Ayyoub M, Routy B, Kroemer G. Microbiome and Anticancer Immunosurveillance. Cell. 2016;165(2):276–87. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the species selected in regression, abundance of Bacteroides ovatus, Bacteroides dorei, Bacteroides massiliensis, Ruminococcus gnavus, and Blautia producta were related to shorter PFS, and Faecalibacterium prausnitzii, Coprococcus eutactus, Prevotella stercorea, Streptococcus sanguinis, Streptococcus anginosus, and Lachnospiraceae bacterium 3 1 46FAA to longer PFS.”
§ Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients > Abstract > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the species selected in regression, abundance of Bacteroides ovatus, Bacteroides dorei, Bacteroides massiliensis, Ruminococcus gnavus, and Blautia producta were related to shorter PFS, and Faecalibacterium prausnitzii, Coprococcus eutactus, Prevotella stercorea, Streptococcus sanguinis, Streptococcus anginosus, and Lachnospiraceae bacterium 3 1 46FAA to longer PFS.”
§ Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients > Abstract > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
70 more claims
Create a free account to see all 104 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 13
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data from the Peters et al. study had indicated the riboflavin (vitamin B2), pantothenate (vitamin B5), pyroxidal 5-phosphate (vitamin B6), and folate (vitamin B9) biosynthesis pathways as being predominantly present in NR (18)”
From Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A meta-analysis found that high abundance of Faecalibacterium genus was the strongest signal associated with response to ICI, using either anti-PD-1 or anti-CTLA-4 antibodies.5–7,12,13”
From Faecalibacterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Bacteroides ovatus, Prevotella copri (renamed Segatella copri), Ruminococcus gnavus (renamed Mediterraneibacter gnavus), and Clostridiumsymbiosum are negatively correlated with ICB efficacy in certain contexts, despite associations with positive outcomes with chemotherapy or other monoclonal antibody therapies in other studies (Di Luccia et al., 2024; Peters et al., 2019; Routy et al.,”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Peters et al., 2019
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recently, the gut microbiota has emerged as a potent new factor associated with the efficacy of anti–CTLA4, anti–PD-1, and anti–PD-L1 treatment (8-14).”
From Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy (2021) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer”
From Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response (2021) · cites this paper as [6]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Each 25 μL PCR reaction contained 9.5 μL of Mo Bio PCR Water (Certified DNA-Free), 12.5 μL of QuantaBio’s AccuStart II PCR ToughMix (2× concentration, 1× final), 1 μL Golay barcode tagged Forward Primer (5 μM concentration, 200 pM final), 1 μL Reverse Primer (5 μM concentration, 200 pM final), and 1 μL of template DNA.”
§ Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients > Methods > 16S rRNA gene sequencing
Reported 200 · recomputed 0.2
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
QIIME allows analysis of high-throughput community sequencing data
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., Costello, E. K., Fierer, N., Peña, A. G., Goodrich, J. K., Gordon, J. I., et al. (2010) · Nature Methods · doi:10.1038/nmeth.f.303 · Cited by 34,887 · cited 1×
“Sequence reads were processed using QIIME 2 [17].”
MethodPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Regularization Paths for Generalized Linear Models via Coordinate Descent
Friedman, J., Hastie, T., & Tibshirani, R. (2010) · Journal of Statistical Software · doi:10.18637/jss.v033.i01 · Cited by 19,927
MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform
Katoh, K. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf436 · Cited by 17,027
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
Research works printed but not linked: 1
- Peters BA, Wilson M, Moran U, Pavlick A, Izsak A, Wechter T, et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients datasets. 2019. Sequence Read Archive. https://www.ncbi.nlm.nih.gov/sra/?term=PRJNA541981 .
Cited by
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., et al. (2021) · Science · doi:10.1126/science.abf3363 · Cited by 1,781
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
Spencer, C. N., McQuade, J. L., Gopalakrishnan, V., McCulloch, J. A., Vetizou, M., Cogdill, A. P., Khan, M. A. W., Zhang, X., White, M. G., Peterson, C. B., et al. (2021) · Science · doi:10.1126/science.aaz7015 · Cited by 966
McCulloch, J. A., Davar, D., Rodrigues, R. R., Badger, J. H., Fang, J. R., Cole, A. M., Balaji, A. K., Vetizou, M., Prescott, S. M., Fernandes, M. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01698-2 · Cited by 472
Lee, K. A., Thomas, A. M., Bolte, L. A., Björk, J. R., de Ruijter, L. K., Armanini, F., Asnicar, F., Blanco-Miguez, A., Board, R., Calbet-Llopart, N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01695-5 · Cited by 464
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01406-6 · Cited by 437
Metadata
- Authors
- Peters, B. A., Wilson, M., Moran, U., Pavlick, A., Izsak, A., Wechter, T., Weber, J. S., Osman, I., & Ahn, J.
- Affiliations
- NYU Langone Health (US)
- Thomas Jefferson University (US)
- Corresponding author
- Ahn, Jiyoung
- ORCID
- Venue
- Genome Medicine
- Published
- 2019-10-09
- Volume
- 11
- Issue
- 1
- Pages
- 61-61
- ISSN
- 1756-994X (ISSN-L)
- PMC
- PMC6785875
- OpenAlex
- W2979785336
- Cited by
- 263
- References
- 49
- Citations by year
- 2026: 34 · 2025: 40 · 2024: 56 · 2023: 47 · 2022: 38 · 2021: 33 · 2020: 12 · 2019: 2
- FWCI
- 7.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Genome Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- The Medicine Forum (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Cancer Institute (P50CA225450, P30CA016087, R01CA164964)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Keywords
- melanoma, immunotherapy response, gut microbiota, gut metagenome, metatranscriptome, progression-free survival, Bacteroides, Faecalibacterium prausnitzii, B vitamin biosynthesis, microbial metabolic pathways
- MeSH terms
- Gastrointestinal Microbiome, Aged, Feces, Female, Humans, Immunotherapy, Male, Melanoma, RNA, Ribosomal, 16S, Metagenome, Transcriptome, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. https://app.cochat.ai/papers/10.1186/s13073-019-0672-4
- The paper
- Peters, B. A., Wilson, M., Moran, U., Pavlick, A., Izsak, A., Wechter, T., Weber, J. S., Osman, I., & Ahn, J. (2019). Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Medicine. https://doi.org/10.1186/s13073-019-0672-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.